Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

ACC 2022 – Complete Trial QoL: Complete Revascularization in STEMI

The COMPLETE study has shown complete revascularization in STEMI reduces cardiovascular mortality or new AMI, which generated a change in ACC/AHA 2021 revascularization guidelines. However, its impact on quality of life is yet to be studied. 

ACC 2022 - Estudio Complete Trial QoL: Revascularización completa en el SCACEST

The aim of this prespecified analysis of the COMPLETE study is to determine whether complete revascularization improves quality of life free from angina compared against a culprit-only revascularization strategy.

The Seattle Angina Questionnaire (SAQ) was used at randomization, 6 months and final visit (mean 3 years). Assessed outcomes included angina related and proportion of patients free from angina events. 

In STEMI patients with multivessel disease both patients with complete revascularization and culprit only revascularization improved angina related quality of life. At 3-year followup, there was a higher proportion of patients free from angina in the complete revascularization group, with NNT 31 patients.

Read also: ACC 2022 | VALOR-HCM: Mavacamten in Adults with Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy

The subgroup analysis showed the greatest impact: benefit was confined to those with a non-culprit lesion ≥80%.

Conclusions

Complete revascularization in STEMI improves quality of life free from angina compared against culprit only revascularization, a benefit that adds to the one previously showed, the reduction of major cardiovascular events. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board, SOLACI.org

Original Title: Complete trail Qol: Complete trail Quality of life  

Reference: Presentado por Dr. Shamir R. Mehta en las sesiones cientificas anuales del American College of Cardiology (ACC 2022), Washington, Abril 2, 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...